Abstract
Alzheimer disease (AD) is the most common neurodegenerative disorder worldwide and is at present, incurable. The accumulation of toxic amyloid-beta (Aβ) peptide aggregates in AD brain is thought to trigger the extensive synaptic loss and neurodegeneration linked to cognitive decline, an idea that underlies the ‘amyloid hypothesis’ of AD etiology in both the familal (FAD) and sporadic forms of the disease. Genetic mutations causing FAD also result in the dysregulation of neuronal calcium (Ca2+) handling and may contribute to AD pathogenesis, an idea termed the ‘calcium hypothesis’ of AD. Mutations in presenilin proteins account for majority of FAD cases. Presenilins function as catalytic subunit of γ-secretase involved in generation of Aβ peptide Recently, we discovered that presenilns function as low-conductance, passive ER Ca2+ leak channels, independent of γ-secretase activity. We further discovered that many FAD mutations in presenilins result in loss of ER Ca2+ leak function activity and Ca2+ overload in the ER. These results provided potential explanation for abnormal Ca2+ signaling observed in FAD cells with mutations in presenilns. Our latest work on studies of ER Ca2+ leak channel function of presenilins and implications of these findings for understanding AD pathogenesis are discussed in this article.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Brookmeyer R, Johnson E, Ziegler-Graham K, et al. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement, 2007, 3: 186–191, 19595937, 10.1016/j.jalz.2007.04.381
Wenk G L. Neuropathologic changes in Alzheimer’s disease. J Clin Psychiatry, 2003, 64Suppl 9: 7–10, 12934968
Giannakopoulos P, Kovari E, Gold G, et al. Pathological substrates of cognitive decline in Alzheimer’s disease. Front Neurol Neurosci, 2009, 24: 20–29, 19182459, 10.1159/000197881
Hardy J. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem, 2009, 110: 1129–1134, 19457065, 10.1111/j.1471-4159.2009.06181.x, 1:CAS:528:DC%2BD1MXpsFOmu70%3D
Hardy J, Selkoe D J. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science, 2002, 297: 353–356, 12130773, 10.1126/science.1072994, 1:CAS:528:DC%2BD38Xls1Cju7s%3D
Small S A, Duff K. Linking Abeta and tau in late-onset Alzheimer’s disease: a dual pathway hypothesis. Neuron, 2008, 60: 534–542, 19038212, 10.1016/j.neuron.2008.11.007, 1:CAS:528:DC%2BD1cXhsV2lsb3M
Bertram L, Tanzi R E. Thirty years of Alzheimer’s disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci, 2008, 9: 768–778, 18802446, 10.1038/nrn2494, 1:CAS:528:DC%2BD1cXhtFeit7fL
Bergmans B A, De Strooper B. gamma-secretases: from cell biology to therapeutic strategies. Lancet Neurol, 2010, 9: 215–226, 20129170, 10.1016/S1474-4422(09)70332-1, 1:CAS:528:DC%2BC3cXitFGhsb8%3D
Hutton M, Lendon C L, Rizzu P, et al. Association of missense and 5’-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 1998, 393: 702–705, 9641683, 10.1038/31508, 1:CAS:528:DyaK1cXktVyqsr0%3D
Cruts M, Van Broeckhoven C. Loss of progranulin function in frontotemporal lobar degeneration. Trends Genet, 2008, 24: 186–194, 18328591, 10.1016/j.tig.2008.01.004, 1:CAS:528:DC%2BD1cXktVKhtbs%3D
Sherrington R, Rogaev E I, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature, 1995, 375: 754–760, 7596406, 10.1038/375754a0, 1:CAS:528:DyaK2MXmvVymtbo%3D
Cruts M, Brouwers N. Alzheimer disease & frontotemporal dementia mutation database. Available at: www.molgen.ua.ac.be/Admutations
Cruts M, Van Broeckhoven C. Presenilin mutations in Alzheimer’s disease. Hum Mutat, 1998, 11: 183–190, 9521418, 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.0.CO;2-J, 1:CAS:528:DyaK1cXhvVeiu7w%3D
Urban S, Schlieper D, Freeman M. Conservation of intramembrane proteolytic activity and substrate specificity in prokaryotic and eukaryotic rhomboids. Curr Biol, 2002, 12: 1507–1512, 12225666, 10.1016/S0960-9822(02)01092-8, 1:CAS:528:DC%2BD38XntVaisb0%3D
Brown M S, Ye J, Rawson R B, et al. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell, 2000, 100: 391–398, 10693756, 10.1016/S0092-8674(00)80675-3, 1:CAS:528:DC%2BD3cXhsVOltbg%3D
Hass M R, Sato C, Kopan R, et al. Presenilin: RIP and beyond. Semin Cell Dev Biol, 2009, 20: 201–210, 19073272, 10.1016/j.semcdb.2008.11.014, 1:CAS:528:DC%2BD1MXksVajtrg%3D
Laudon H, Hansson E M, Melen K, et al. A nine-transmembrane domain topology for presenilin 1. J Biol Chem, 2005, 280: 35352–35360, 16046406, 10.1074/jbc.M507217200, 1:CAS:528:DC%2BD2MXhtFWmur7L
Spasic D, Tolia A, Dillen K, et al. Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway. J Biol Chem, 2006, 281: 26569–26577, 16846981, 10.1074/jbc.M600592200, 1:CAS:528:DC%2BD28XovF2js7s%3D
Annaert W G, Levesque L, Craessaerts K, et al. Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J Cell Biol, 1999, 147: 277–294, 10525535, 10.1083/jcb.147.2.277, 1:CAS:528:DyaK1MXmslCqs78%3D
Thinakaran G, Borchelt D R, Lee M K, et al. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron, 1996, 17: 181–190, 8755489, 10.1016/S0896-6273(00)80291-3, 1:CAS:528:DyaK28Xks1eksb8%3D
De Strooper B, Beullens M, Contreras B, et al. Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer’s disease-associated presenilins. J Biol Chem, 1997, 272: 3590–3598, 9013610, 10.1074/jbc.272.6.3590
Yu G, Chen F, Levesque G, et al. The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin. J Biol Chem, 1998, 273: 16470–16475, 9632714, 10.1074/jbc.273.26.16470, 1:CAS:528:DyaK1cXkt1GmtLc%3D
Kimberly W T, LaVoie M J, Ostaszewski B L, et al. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci USA, 2003, 100: 6382–6387, 12740439, 10.1073/pnas.1037392100, 1:CAS:528:DC%2BD3sXktlyhtLg%3D
Edbauer D, Winkler E, Regula J T, et al. Reconstitution of gamma-secretase activity. Nat Cell Biol, 2003, 5: 486–488, 12679784, 10.1038/ncb960, 1:CAS:528:DC%2BD3sXjtlamu70%3D
Takasugi N, Tomita T, Hayashi I, et al. The role of presenilin cofactors in the gamma-secretase complex. Nature, 2003, 422: 438–441, 12660785, 10.1038/nature01506, 1:CAS:528:DC%2BD3sXitlGgtb0%3D
Lazarov V K, Fraering P C, Ye W, et al. Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci USA, 2006, 103: 6889–6894, 16636269, 10.1073/pnas.0602321103, 1:CAS:528:DC%2BD28XkslCksL0%3D
Wolfe M S, Xia W, Ostaszewski B L, et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature, 1999, 398: 513–517, 10206644, 10.1038/19077, 1:CAS:528:DyaK1MXisFGqt7g%3D
De Strooper B, Saftig P, Craessaerts K, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature, 1998, 391: 387–390, 9450754, 10.1038/34910
Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med, 1996, 2: 864–870, 8705854, 10.1038/nm0896-864, 1:CAS:528:DyaK28XkslGiu7g%3D
Supnet C, Bezprozvanny I. The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium, 2010, 47: 183–189, 20080301, 10.1016/j.ceca.2009.12.014, 1:CAS:528:DC%2BC3cXjtVSms7g%3D
Bezprozvanny I, Mattson M P. Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease. Trends Neurosci, 2008, 31: 454–463, 18675468, 10.1016/j.tins.2008.06.005, 1:CAS:528:DC%2BD1cXhtVKnurzI
Stutzmann G E. The pathogenesis of Alzheimers disease is it a lifelong “calciumopathy”? Neuroscientist, 2007, 13: 546–559, 17901262, 10.1177/1073858407299730, 1:CAS:528:DC%2BD2sXhtFyju73L
Demuro A, Parker I, Stutzmann G E. Calcium signaling and amyloid toxicity in Alzheimer disease. J Biol Chem, 2010, 285: 12463–12468, 20212036, 10.1074/jbc.R109.080895, 1:CAS:528:DC%2BC3cXkvVGjt7s%3D
Ito E, Oka K, Etcheberrigaray R, et al. Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc Natl Acad Sci USA, 1994, 91: 534–538, 8290560, 10.1073/pnas.91.2.534, 1:CAS:528:DyaK2cXhtlWgtrg%3D
Etcheberrigaray R, Hirashima N, Nee L, et al. Calcium responses in fibroblasts from asymptomatic members of Alzheimer’s disease families. Neurobiol Dis, 1998, 5: 37–45, 9702786, 10.1006/nbdi.1998.0176, 1:CAS:528:DyaK1cXlsVOrtrg%3D
Khachaturian Z S. Calcium, membranes, aging, and Alzheimer’s disease. Introduction and overview. Ann N Y Acad Sci, 1989, 568: 1–4, 2629579, 10.1111/j.1749-6632.1989.tb12485.x, 1:STN:280:DyaK3c7ps1OqsA%3D%3D
Supnet C, Bezprozvanny I. Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer’s disease. J Alzheimers Dis, 2010, 20Suppl 2: S487–S498, 20413848
Stutzmann G E, Caccamo A, LaFerla F M, et al. Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer’s-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci, 2004, 24: 508–513, 14724250, 10.1523/JNEUROSCI.4386-03.2004, 1:CAS:528:DC%2BD2cXpvVyjtA%3D%3D
Stutzmann G E, Smith I, Caccamo A, et al. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer’s disease mice. J Neurosci, 2006, 26: 5180–5189, 16687509, 10.1523/JNEUROSCI.0739-06.2006, 1:CAS:528:DC%2BD28Xlt1Cju7Y%3D
Chakroborty S, Goussakov I, Miller M B, et al. Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3×Tg-AD mice. J Neurosci, 2009, 29: 9458–9470, 19641109, 10.1523/JNEUROSCI.2047-09.2009, 1:CAS:528:DC%2BD1MXpsFOntrc%3D
Smith I F, Hitt B, Green K N, et al. Enhanced caffeine-induced Ca2+ release in the 3×Tg-AD mouse model of Alzheimer’s disease. J Neurochem, 2005, 94: 1711–1718, 16156741, 10.1111/j.1471-4159.2005.03332.x, 1:CAS:528:DC%2BD2MXhtVaksbvF
Chan S L, Mayne M, Holden C P, et al. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J Biol Chem, 2000, 275: 18195–18200, 10764737, 10.1074/jbc.M000040200, 1:CAS:528:DC%2BD3cXktlymtLc%3D
Lee S Y, Hwang D Y, Kim Y K, et al. PS2 mutation increases neuronal cell vulnerability to neurotoxicants through activation of caspase-3 by enhancing of ryanodine receptor-mediated calcium release. FASEB J, 2006, 20: 151–153, 16394273, 10.1096/fj.05-4017fje;1, 1:CAS:528:DC%2BD28XhtFelsbc%3D
Leissring M A, Parker I, LaFerla F M. Presenilin-2 mutations modulate amplitude and kinetics of inositol 1,4,5-trisphosphate-mediated calcium signals. J Biol Chem, 1999, 274: 32535–32538, 10551803, 10.1074/jbc.274.46.32535, 1:CAS:528:DyaK1MXntlygsL8%3D
Leissring M A, Akbari Y, Fanger C M, et al. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J Cell Biol, 2000, 149: 793–798, 10811821, 10.1083/jcb.149.4.793, 1:CAS:528:DC%2BD3cXjtlKnsro%3D
Zatti G, Ghidoni R, Barbiero L, et al. The presenilin 2 M239I mutation associated with familial Alzheimer’s disease reduces Ca2+ release from intracellular stores. Neurobiol of Dis, 2004, 15: 269–278, 10.1016/j.nbd.2003.11.002, 1:CAS:528:DC%2BD2cXhvFSktLY%3D
Giacomello M, Barbiero L, Zatti G, et al. Reduction of Ca2+ stores and capacitative Ca2+ entry is associated with the familial Alzheimer’s disease presenilin-2 T122R mutation and anticipates the onset of dementia. Neurobiol Dis, 2005, 18: 638–648, 15755689, 10.1016/j.nbd.2004.10.016, 1:CAS:528:DC%2BD2MXhvFyntr8%3D
Yoo A S, Cheng I, Chung S, et al. Presenilin-mediated modulation of capacitative calcium entry. Neuron, 2000, 27: 561–572, 11055438, 10.1016/S0896-6273(00)00066-0, 1:CAS:528:DC%2BD3cXnt12ntL8%3D
Herms J, Schneider I, Dewachter I, et al. Capacitive calcium entry is directly attenuated by mutant presenilin-1, independent of the expression of the amyloid precursor protein. J Biol Chem, 2003, 278: 2484–2489, 12431992, 10.1074/jbc.M206769200, 1:CAS:528:DC%2BD3sXksFanuw%3D%3D
Akbari Y, Hitt B D, Murphy M P, et al. Presenilin regulates capacitative calcium entry dependently and independently of gamma-secretase activity. Biochem Biophys Res Commun, 2004, 322: 1145–1152, 15336962, 10.1016/j.bbrc.2004.07.136, 1:CAS:528:DC%2BD2cXntFeqtbY%3D
Zhang H, Sun S, Herreman A, et al. Role of presenilins in neuronal calcium homeostasis. J Neurosci, 2010, 30: 8566–8580, 20573903, 10.1523/JNEUROSCI.1554-10.2010, 1:CAS:528:DC%2BC3cXos1Knur0%3D
Goussakov I, Miller M B, Stutzmann G E. NMDA-mediated Ca2+ influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer’s disease mice. J Neurosci, 2010, 30: 12128–12137, 20826675, 10.1523/JNEUROSCI.2474-10.2010, 1:CAS:528:DC%2BC3cXhtF2qsLfP
Cheung K H, Shineman D, Muller M, et al. Mechanism of Ca2+ disruption in Alzheimer’s disease by presenilin regulation of InsP(3) receptor channel gating. Neuron, 2008, 58: 871–883, 18579078, 10.1016/j.neuron.2008.04.015, 1:CAS:528:DC%2BD1cXotFyrsLw%3D
Cheung K H, Mei L, Mak D O, et al. Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer’s disease-linked presenilin mutants in human cells and mouse neurons. Sci Signal, 2010, 3: ra22, 20332427, 10.1126/scisignal.2000818
Green K N, Demuro A, Akbari Y, et al. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Cell Biol, 2008, 181: 1107–1116, 18591429, 10.1083/jcb.200706171, 1:CAS:528:DC%2BD1cXotF2it78%3D
Tu H, Nelson O, Bezprozvanny A, et al. Presenilins form ER calcium leak channels, a function disrupted by mutations linked to familial Alzheimer’s disease. Cell, 2006, 126: 981–993, 16959576, 10.1016/j.cell.2006.06.059, 1:CAS:528:DC%2BD28XpvVKiuro%3D
Nelson O, Tu H, Lei T, et al. Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1. J Clin Invest, 2007, 117: 1230–1239, 17431506, 10.1172/JCI30447, 1:CAS:528:DC%2BD2sXlt1Omt7g%3D
Nelson O, Supnet C, Liu H, et al. Familial Alzheimer’s disease mutations in presenilins: effects on endoplasmic reticulum calcium homeostasis and correlation with clinical phenotypes. J Alzheimers Dis, 2010, 21: 781–793, 20634584, 1:CAS:528:DC%2BC3cXhtFKmurjK
Tolia A, Chavez-Gutierrez L, De Strooper B. Contribution of presenilin transmembrane domains 6 and 7 to a water-containing cavity in the {gamma}-secretase complex. J Biol Chem, 2006, 281: 27633–27642, 16844686, 10.1074/jbc.M604997200, 1:CAS:528:DC%2BD28XptlKmtbc%3D
Tolia A, Horre K, De Strooper B. Transmembrane domain 9 of presenilin determines the dynamic conformation of the catalytic site of gamma-secretase. J Biol Chem, 2008, 283: 19793–19803, 18482978, 10.1074/jbc.M802461200, 1:CAS:528:DC%2BD1cXotF2ktL4%3D
Sato C, Takagi S, Tomita T, et al. The C-terminal PAL motif and transmembrane domain 9 of presenilin 1 are involved in the formation of the catalytic pore of the gamma-secretase. J Neurosci, 2008, 28: 6264–6271, 18550769, 10.1523/JNEUROSCI.1163-08.2008, 1:CAS:528:DC%2BD1cXns1ynsrk%3D
Sato C, Morohashi Y, Tomita T, et al. Structure of the catalytic pore of gamma-secretase probed by the accessibility of substituted cysteines. J Neurosci, 2006, 26: 12081–12088, 17108181, 10.1523/JNEUROSCI.3614-06.2006, 1:CAS:528:DC%2BD28Xht1yksr7N
Akabas M H, Stauffer D A, Xu M, et al. Acetylcholine receptor channel structure probed in cysteine-substitution mutants. Science, 1992, 258: 307–310, 1384130, 10.1126/science.1384130, 1:CAS:528:DyaK38Xmt1Knurg%3D
Akabas M H, Kaufmann C, Archdeacon P, et al. Identification of acetylcholine receptor channel-lining residues in the entire M2 segment of the alpha subunit. Neuron, 1994, 13: 919–927, 7524560, 10.1016/0896-6273(94)90257-7, 1:CAS:528:DyaK2MXitVOgtrk%3D
Sobhanifar S, Schneider B, Lohr F, et al. Structural investigation of the C-terminal catalytic fragment of presenilin 1. Proc Natl Acad Sci USA, 2010, 107: 9644–9649, 20445084, 10.1073/pnas.1000778107, 1:CAS:528:DC%2BC3cXntFGqsLs%3D
Nelson O, Supnet C, Tolia A, et al. Mutagenesis mapping of the presenilin 1 calcium leak conductance pore. J Biol Chem, 2011, 286: 22339–22347, 21531718, 10.1074/jbc.M111.243063, 1:CAS:528:DC%2BC3MXns1Kksb0%3D
De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-secretase complex. Neuron, 2003, 38: 9–12, 12691659, 10.1016/S0896-6273(03)00205-8
Herl L, Lleo A, Thomas A V, et al. Detection of presenilin-1 homodimer formation in intact cells using fluorescent lifetime imaging microscopy. Biochem Biophys Res Commun, 2006, 340: 668–674, 16376853, 10.1016/j.bbrc.2005.12.063, 1:CAS:528:DC%2BD28XhvFKltA%3D%3D
Cervantes S, Gonzalez-Duarte R, Marfany G. Homodimerization of presenilin N-terminal fragments is affected by mutations linked to Alzheimer’s disease. FEBS Lett, 2001, 505: 81–86, 11557046, 10.1016/S0014-5793(01)02785-5, 1:CAS:528:DC%2BD3MXmslehs7w%3D
Hebert S S, Godin C, Tomiyama T, et al. Dimerization of presenilin-1 in vivo: suggestion of novel regulatory mechanisms leading to higher order complexes. Biochem Biophys Res Commun, 2003, 301: 119–126, 12535650, 10.1016/S0006-291X(02)02984-4, 1:CAS:528:DC%2BD3sXjtFersg%3D%3D
Cervantes S, Saura C A, Pomares E, et al. Functional implications of the presenilin dimerization: reconstitution of gamma-secretase activity by assembly of a catalytic site at the dimer interface of two catalytically inactive presenilins. J Biol Chem, 2004, 279: 36519–36529, 15220354, 10.1074/jbc.M404832200, 1:CAS:528:DC%2BD2cXmvFCnu7c%3D
Takagi S, Tominaga A, Sato C, et al. Participation of transmembrane domain 1 of presenilin 1 in the catalytic pore structure of the {gamma}-secretase. J Neurosci, 2010, 30: 15943–15950, 21106832, 10.1523/JNEUROSCI.3318-10.2010, 1:CAS:528:DC%2BC3cXhsFCiurbE
Larner A J, Doran M. Clinical phenotypic heterogeneity of Alzheimer’s disease associated with mutations of the presenilin-1 gene. J Neurol, 2006, 253: 139–158, 16267640, 10.1007/s00415-005-0019-5, 1:CAS:528:DC%2BD28XjtFegtb8%3D
Ryan N S, Rossor M N. Correlating familial Alzheimer’s disease gene mutations with clinical phenotype. Biomark Med, 2010, 4: 99–112, 20387306, 10.2217/bmm.09.92, 1:CAS:528:DC%2BC3cXhsFCnurg%3D
Shepherd C, McCann H, Halliday G M. Variations in the neuropathology of familial Alzheimer’s disease. Acta Neuropathol, 2009, 118: 37–52, 19306098, 10.1007/s00401-009-0521-4, 1:CAS:528:DC%2BD1MXmt1ahu7o%3D
Houlden H, Baker M, McGowan E, et al. Variant Alzheimer’s disease with spastic paraparesis and cotton wool plaques is caused by PS-1 mutations that lead to exceptionally high amyloid-beta concentrations. Ann Neurol, 2000, 48: 806–808, 11079548, 10.1002/1531-8249(200011)48:5<806::AID-ANA18>3.0.CO;2-F, 1:CAS:528:DC%2BD3cXosFSgtL8%3D
Kwok J B, Taddei K, Hallupp M, et al. Two novel (M233T and R278T) presenilin-1 mutations in early-onset Alzheimer’s disease pedigrees and preliminary evidence for association of presenilin-1 mutations with a novel phenotype. Neuroreport, 1997, 8: 1537–1542, 9172170, 10.1097/00001756-199704140-00043, 1:CAS:528:DyaK2sXjvVOhu7s%3D
Crook R, Verkkoniemi A, Perez-Tur J, et al. A variant of Alzheimer’s disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med, 1998, 4: 452–455, 9546792, 10.1038/nm0498-452, 1:CAS:528:DyaK1cXisVeluro%3D
Verkkoniemi A, Kalimo H, Paetau A, et al. Variant Alzheimer disease with spastic paraparesis: neuropathological phenotype. J Neuropathol Exp Neurol, 2001, 60: 483–492, 11379823, 1:STN:280:DC%2BD3M3ps1aisg%3D%3D
Karlstrom H, Brooks W S, Kwok J B, et al. Variable phenotype of Alzheimer’s disease with spastic paraparesis. J Neurochem, 2008, 104: 573–83, 17995932, 1:CAS:528:DC%2BD1cXhvF2ku7Y%3D
Tabira T, Chui D H, Nakayama H, et al. Alzheimer’s disease with spastic paresis and cotton wool type plaques. J Neurosci Res, 2002, 70: 367–372, 12391599, 10.1002/jnr.10392, 1:CAS:528:DC%2BD38XosVaqu70%3D
Ataka S, Tomiyama T, Takuma H, et al. A novel presenilin-1 mutation (Leu85Pro) in early-onset Alzheimer disease with spastic paraparesis. Arch Neurol, 2004, 61: 1773–1776, 15534188, 10.1001/archneur.61.11.1773
Halliday G M, Song Y J, Lepar G, et al. Pick bodies in a family with presenilin-1 Alzheimer’s disease. Ann Neurol, 2005, 57: 139–143, 15622541, 10.1002/ana.20366, 1:CAS:528:DC%2BD2MXpsFSrsQ%3D%3D
Le T V, Crook R, Hardy J, et al. Cotton wool plaques in non-familial late-onset Alzheimer disease. J Neuropathol Exp Neurol, 2001, 60: 1051–1061, 11706935, 1:STN:280:DC%2BD3MnlsVegtg%3D%3D
Brooks W S, Kwok J B, Kril J J, et al. Alzheimer’s disease with spastic paraparesis and ‘cotton wool’ plaques: two pedigrees with PS-1 exon 9 deletions. Brain, 2003, 126: 783–791, 12615638, 10.1093/brain/awg084
Jacquemont M L, Campion D, Hahn V, et al. Spastic paraparesis and atypical dementia caused by PSEN1 mutation (P264L), responsible for Alzheimer’s disease. J Med Genet, 2002, 39: E2, 11836371, 10.1136/jmg.39.2.e2, 1:STN:280:DC%2BD387htF2jsg%3D%3D
Takao M, Ghetti B, Hayakawa I, Ikeda E, et al. A novel mutation (G217D) in the Presenilin 1 gene ( PSEN1) in a Japanese family: presenile dementia and parkinsonism are associated with cotton wool plaques in the cortex and striatum. Acta Neuropathol, 2002, 104: 155–170, 12111359, 10.1007/s00401-002-0536-6, 1:CAS:528:DC%2BD38XkvFKqsbg%3D
Toescu E C, Verkhratsky A. The importance of being subtle: small changes in calcium homeostasis control cognitive decline in normal aging. Aging Cell, 2007, 6: 267–273, 17517038, 10.1111/j.1474-9726.2007.00296.x, 1:CAS:528:DC%2BD2sXntVKqu70%3D
Gant J C, Sama M M, Landfield P W, et al. Early and simultaneous emergence of multiple hippocampal biomarkers of aging is mediated by Ca2+-induced Ca2+ release. J Neurosci, 2006, 26: 3482–3490, 16571755, 10.1523/JNEUROSCI.4171-05.2006, 1:CAS:528:DC%2BD28Xjslaiu7Y%3D
Foster T C. Calcium homeostasis and modulation of synaptic plasticity in the aged brain. Aging Cell, 2007, 6: 319–325, 17517041, 10.1111/j.1474-9726.2007.00283.x, 1:CAS:528:DC%2BD2sXntVKqu7Y%3D
Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med, 2009, 15: 89–100, 19230774, 10.1016/j.molmed.2009.01.001, 1:CAS:528:DC%2BD1MXjt1ahu7s%3D
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Supnet, C., Bezprozvanny, I. Presenilins as endoplasmic reticulum calcium leak channels and Alzheimer’s disease pathogenesis. Sci. China Life Sci. 54, 744–751 (2011). https://doi.org/10.1007/s11427-011-4201-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-011-4201-y